Search results for Ramucirumab

Ramucirumab Biosimilar – Anti-VEGFR-2 mAb – Research Grade, ProteoGenix, PX-TA1023

Description of Ramucirumab Biosimilar - Anti-VEGFR-2 mAb - Research Grade General information about Ramucirumab Ramucirumab is a monoclonal antibody. Monoclonal antibodies are created in a lab to attach to the targets found on specific types of cancer cells. The antibody “calls” the immune system to attack the cell it is attached to, resulting in the immune system killing the cell. These antibodies can work in different ways, including stimulating the immune system to kill the cell, blocking cell growth or other functions necessary for cell growth. Ramucirumab inhibits the activity of vascular endothelial growth factor (VEGF). VEGF is responsible for angiogenesis, or the development of new blood vessels by and for the tumor (or any tissue), so blocking VEGF’s activity prevents the growth of new blood vessels, essentially cutting off the tumor’s source of nutrients. This product is for research use only.

Ramucirumab, Abbexa, abx831167

Ramucirumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting KDR/CD309, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells. VEGFR stimulation also mediates downstream signalling required for angiogenesis and is postulated to be heavily involved in cancer progression, making it a highly likely drug target. In contrast to other agents directed against VEGFR-2, ramucirumab binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it. Ramucirumab is indicated for us in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing chemotherapy.

Ramucirumab, Kyinno, KB-1169

Ramucirumab, Affinityimmuno, ab-131-ramucirumab

Ramucirumab ELISA Kit, ProteoGenix, KPTX225

Description of Ramucirumab ELISA Kit Ramucirumab ELISA Kit Introduction The Ramucirumab ELISA Kit is a highly sensitive and specific assay used for the quantitative measurement of Ramucirumab in various biological samples. Ramucirumab is a monoclonal antibody that specifically targets the vascular endothelial growth factor receptor 2 (VEGFR-2) and is used as a therapeutic agent in the treatment of various types of cancer. Structure of Ramucirumab Ramucirumab is a human IgG1 monoclonal antibody with a molecular weight of approximately 149 kDa. It is composed of two heavy chains and two light chains, each containing a variable and constant region. The variable region is responsible for binding to the VEGFR-2 receptor, while the constant region is responsible for effector functions such as binding to Fc receptors and complement activation. Activity of Ramucirumab Ramucirumab works by binding to the VEGFR-2 receptor and inhibiting the binding of its ligands, VEGF-A, VEGF-C, and VEGF-D. This prevents the activation of downstream signaling pathways involved in angiogenesis, the formation of new blood vessels that supply nutrients and oxygen to tumors. By inhibiting angiogenesis, Ramucirumab reduces the blood supply to tumors, leading to tumor shrinkage and inhibition of tumor growth. Application of Ramucirumab ELISA Kit The Ramucirumab ELISA Kit is primarily used for the quantitative measurement of Ramucirumab in human serum, plasma, and other biological samples. It is a valuable tool for monitoring the levels of Ramucirumab in patients undergoing treatment with this therapeutic antibody. The kit is also used in preclinical studies to assess the pharmacokinetics and pharmacodynamics of Ramucirumab in animal models. Benefits of using Ramucirumab ELISA Kit Highly sensitive and specific assay Quantitative measurement of Ramucirumab Can be used for various biological samples Allows for monitoring of Ramucirumab levels in patients Useful in preclinical studies Procedure of Ramucirumab ELISA Kit The Ramucirumab ELISA Kit follows a sandwich immunoassay principle. The kit contains pre-coated plates with antibodies specific for Ramucirumab. The samples, along with standards of known concentrations, are added to the wells and incubated. Ramucirumab present in the sample binds to the antibodies on the plate, forming a sandwich complex. After washing away any unbound substances, an enzyme-linked secondary antibody is added, which binds to the sandwich complex. The addition of a substrate results in the production of a color change, which is measured using a spectrophotometer. The intensity of the color is directly proportional to the concentration of Ramucirumab in the sample. Conclusion The Ramucirumab ELISA Kit is a valuable tool for the quantitative measurement of Ramucirumab in various biological samples. It allows for the monitoring of Ramucirumab levels in patients undergoing treatment and aids in preclinical studies. With its high sensitivity and specificity, the kit provides accurate and reliable results, making it an essential tool for researchers and clinicians working with Ramucirumab as a therapeutic antibody.

Ramucirumab ELISA Kit, Abbexa, abx395114

Ramucirumab ELISA Kit is a quantitative ELISA kit for detection of Ramucirumab.Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II transmembrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, Ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells.

Anti-Ramucirumab Polyclonal Antibody, AntibodySystem, PAE16601

Ramucirumab Biosimilar - Research Grade, ichor.bio, ICH4032

Detects human VEGFR2. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Ramucirumab.